- In July 2024, Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) had approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. LEQSELVI, a JAK inhibitor, targets the root cause of alopecia areata and has been clinically proven to provide statistically significant efficacy
- In June 2024, according to a published report in the The Harvard Gazette, Harvard researchers have developed a groundbreaking treatment to reverse hair loss caused by alopecia areata, an autoimmune condition. The team created a microneedle patch that promotes the regrowth of hair by enhancing immune cell recruitment to hair follicles. The patch showed promising results in reversing hair loss in mice and demonstrated excellent stability, offering hope for future clinical applications in humans. This discovery could revolutionize treatment for alopecia areata
- In June 2024, Equillium Inc. announced positive topline results from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate to very-severe alopecia areata (AA), an autoimmune condition where immune cells attack hair follicles, leading to hair loss
- In June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had granted approval for LITFULO (ritlecitinib), a once-daily oral treatment for individuals aged 12 and older with severe alopecia areata. The recommended dosage for LITFULO is 50 mg. This marks it as the first and only FDA-approved treatment for adolescents (12+) suffering from severe alopecia areata
- In June 2022, Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) had approved OLUMIANT (baricitinib), a once-daily oral treatment, as the first systemic therapy for adults with severe alopecia areata (AA). The medication is available in 4-mg, 2-mg, and 1-mg tablets, with a recommended starting dose of 2 mg per day, which can be increased to 4 mg per day if the treatment response is insufficient
